跳至主要内容
临床试验/NCT06037876
NCT06037876已完成3 期

Efficacy of the Combination Ivermectin and Albendazole vs Albendazole Alone in School-aged Children Infected With Trichuris Trichiura: a Randomized Controlled Trial

Jennifer Keiser1 个研究点 分布在 1 个国家目标入组 161 人开始时间: 2023年10月9日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
161
试验地点
1
主要终点
Number of Participants T. Trichiura Egg Negative Post-Treatment (Cured)

研究概览

简要总结

The goal of this parallel open-label randomized controlled superiority trial is to demonstrate that co-administered ivermectin (200 µg/kg) plus albendazole (400 mg) is superior to albendazole (400 mg) monotherapy in terms of cure rates against Trichuris trichiura infections assessed by Kato-Katz at 14-21 days post-treatment in individuals aged 6-12 years.

The main questions it aims to answer are:

  • Is single oral dose combined ivermectin-albendazole superior to albendazole alone in terms of cure rates and egg reduction rates against T. trichiura infections in children aged 6-12 years in Uganda?
  • Is single oral dose combined ivermectin-albendazole superior to albendazole alone in terms of cure rates and egg reduction rates against co-infecting soil-transmitted helminth infections such as Ascaris lumbricoides and hookworm in children aged 6-12 years in Uganda?
  • Is single oral dose combined ivermectin-albendazole as tolerable and safe as albendazole monotherapy in children aged 6-12 years in Uganda?

Participants will be asked to provide two stool samples at baseline that will be subjected to microscopic analysis using the Kato-Katz thick smear technique for detection of soil-transmitted helminth eggs. T. trichiura-infected participants will be:

  • clinically examined for general health, anthropometric parameters including height and weight as well as temperature
  • randomly assigned to either receive one single oral dose of combined ivermectin and albendazole or albendazole monotherapy
  • checked for any potential adverse events and will undergo a brief questionnaire on specific symptoms 3h after drug administration
  • asked to provide another two stool samples to be microscopically examined for helminth eggs 14-21 days post-treatment Researchers will compare individuals treated with ivermectin-albendazole and albendazole alone to see if the proportion of T. trichiura egg-negative individuals and/or reduction in egg counts differs between these two groups 14-21 days after treatment.

详细描述

In view that efficacy of co-administered ivermectin (IVM) and albendazole (ALB) has been found to vary between different settings the rationale of this parallel open-label randomized controlled superiority trial is to provide evidence on the efficacy of co-administered ivermectin and albendazole compared to albendazole monotherapy in school-aged children aged 6-12 years against infection with T. trichiura in Uganda.

Our primary objective is to demonstrate superiority of

  1. Arm A: single dose of ivermectin (200 µg/kg, 3 mg tablets according to weight) / single dose of albendazole (400 mg tablet) combination, compared to
  2. Arm B: single dose of albendazole (400 mg tablet)

in terms of cure rate (CR) against T. trichiura infections in school-aged children aged 6-12 years assessed at 14-21 days post-treatment by Kato-Katz microscopy.

The secondary objectives of the trial are:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

盲法说明

Allocation concealment will be warranted using sequential, opaque, sealed envelopes. Outcome assessors in the lab will be blinded.

入排标准

年龄范围
6 Years 至 12 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Written informed consent for participation signed from caregivers; and written assent by participants.
  • Agree to comply with study procedures, including provision of two stool samples at the beginning (baseline) and at follow-up assessment 14-21 days after treatment.
  • Willing to be examined by a study nurse/physician prior to treatment.
  • At least two slides of the quadruple Kato-Katz thick smears positive for T. trichiura.

排除标准

  • Presence or signs of major systemic illnesses, e.g. body temperature ≥ 38°C, clinical malaria (fever + positive RDT) upon initial clinical assessment.
  • Recent use of anthelmintic drug (within past 4 weeks).
  • Attending other experimental research studies.
  • Known allergy to study medications (i.e. benzimidazole or ivermectin).

研究组 & 干预措施

ALB (400mg)

Active Comparator

A single tablet of albendazole (400mg), provided as single oral dose.

干预措施: ALB (400mg) (Drug)

IVM (200 µg/kg) + ALB (400 mg)

Experimental

A single tablet of albendazole (400mg) plus 200 µg/kg of ivermectin, provided as single oral dose.

干预措施: IVM (200 µg/kg) + ALB (400 mg) (Drug)

结局指标

主要结局

Number of Participants T. Trichiura Egg Negative Post-Treatment (Cured)

时间窗: 14-21 days after treatment

The conversion from being egg positive pre-treatment to egg negative post-treatment, or cure rate (CR).

次要结局

  • Egg Reduction Rate (ERR) against T. Trichiura(14-21 days after treatment)
  • Number of Participants With Concomitant Soil-transmitted Helminth Infections Egg Negative Post-Treatment (Cured)(14-21 days after treatment)
  • Egg-reduction Rates (ERRs) Against Concomitant Soil-transmitted Helminth Infections(14-21 days after treatment)

研究者

发起方
Jennifer Keiser
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Jennifer Keiser

Prof. Dr.

Swiss Tropical & Public Health Institute

研究点 (1)

Loading locations...

相似试验